Is Grown Rogue International (CSE:GRIN) Using Debt Sensibly?
Dec 25
Have your own idea? Try our Stock Screener
Canadian (TSX) Pharma Industry Analysis
UpdatedJan 02, 2026
DataAggregated Company Financials
Companies58
- 7D-2.3%
- 3M-9.0%
- 1Y4.9%
- YTDn/a
Over the last 7 days, the Pharma industry has dropped 2.3%, driven by a pullback from Curaleaf Holdings of 9.3%. Meanwhile, Trulieve Cannabis actually outperformed within the industry, gaining 9.3% in the last week. This takes the industry's 12 month performance to a gain of 9.2%. Earnings are forecast to grow by 67% annually.
Industry Valuation and Performance
Has the Canadian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 02 Jan 2026 | CA$16.1b | CA$11.2b | -CA$1,941,107,247.25 | 16.6x | -8.3x | 1.4x |
| Sun, 30 Nov 2025 | CA$13.6b | CA$11.3b | -CA$1,932,530,784.66 | 14.7x | -7x | 1.2x |
| Tue, 28 Oct 2025 | CA$16.7b | CA$11.3b | -CA$2,039,204,685.76 | 32x | -8.2x | 1.5x |
| Thu, 25 Sep 2025 | CA$15.8b | CA$11.3b | -CA$2,040,557,398.98 | 38.5x | -7.8x | 1.4x |
| Sat, 23 Aug 2025 | CA$17.0b | CA$11.9b | -CA$2,548,234,474.06 | 37.4x | -6.7x | 1.4x |
| Mon, 21 Jul 2025 | CA$10.4b | CA$11.7b | -CA$2,547,021,881.32 | 19.2x | -4.1x | 0.9x |
| Wed, 18 Jun 2025 | CA$9.8b | CA$11.7b | -CA$2,511,882,068.22 | 18.4x | -3.9x | 0.8x |
| Fri, 16 May 2025 | CA$9.1b | CA$10.3b | -CA$2,198,514,655.36 | 17.5x | -4.2x | 0.9x |
| Sun, 13 Apr 2025 | CA$9.0b | CA$12.0b | -CA$2,577,138,685.78 | 18.3x | -3.5x | 0.7x |
| Tue, 11 Mar 2025 | CA$11.1b | CA$12.4b | -CA$2,670,029,180.56 | 21.6x | -4.2x | 0.9x |
| Thu, 06 Feb 2025 | CA$12.3b | CA$12.1b | -CA$2,320,021,311.40 | 23.6x | -5.3x | 1x |
| Sat, 04 Jan 2025 | CA$13.6b | CA$12.2b | -CA$2,418,880,778.87 | 29.2x | -5.6x | 1.1x |
| Mon, 02 Dec 2024 | CA$14.3b | CA$11.9b | -CA$2,566,334,890.65 | 21.1x | -5.6x | 1.2x |
| Wed, 30 Oct 2024 | CA$20.0b | CA$11.9b | -CA$2,722,226,749.68 | 18.5x | -7.3x | 1.7x |
| Fri, 27 Sep 2024 | CA$18.2b | CA$11.6b | -CA$2,685,092,434.05 | 27.7x | -6.8x | 1.6x |
| Sun, 25 Aug 2024 | CA$18.4b | CA$11.5b | -CA$2,732,773,282.31 | 22.9x | -6.7x | 1.6x |
| Tue, 23 Jul 2024 | CA$19.9b | CA$11.7b | -CA$3,198,104,383.11 | 19x | -6.2x | 1.7x |
| Thu, 20 Jun 2024 | CA$19.3b | CA$11.8b | -CA$2,766,913,694.70 | 12.7x | -7x | 1.6x |
| Sat, 18 May 2024 | CA$25.6b | CA$11.9b | -CA$3,513,584,769.18 | 14.5x | -7.3x | 2.2x |
| Mon, 15 Apr 2024 | CA$23.6b | CA$12.0b | -CA$3,480,018,729.69 | 9x | -6.8x | 2x |
| Wed, 13 Mar 2024 | CA$18.8b | CA$11.9b | -CA$3,898,363,199.45 | 7.1x | -4.8x | 1.6x |
| Fri, 09 Feb 2024 | CA$24.0b | CA$11.9b | -CA$5,862,666,340.75 | 12.9x | -4.1x | 2x |
| Sun, 07 Jan 2024 | CA$19.9b | CA$12.3b | -CA$6,734,378,985.00 | 9.9x | -3x | 1.6x |
| Tue, 05 Dec 2023 | CA$18.1b | CA$12.4b | -CA$6,770,158,385.00 | 8.8x | -2.7x | 1.5x |
| Thu, 02 Nov 2023 | CA$15.6b | CA$12.5b | -CA$7,379,166,804.00 | 10.9x | -2.1x | 1.2x |
| Sat, 30 Sep 2023 | CA$20.0b | CA$12.3b | -CA$7,343,960,094.00 | 13.9x | -2.7x | 1.6x |
| Mon, 28 Aug 2023 | CA$13.8b | CA$13.1b | -CA$8,126,028,354.00 | 14.7x | -1.7x | 1.1x |
| Wed, 26 Jul 2023 | CA$14.4b | CA$13.1b | -CA$9,699,280,144.00 | 11.6x | -1.5x | 1.1x |
| Fri, 23 Jun 2023 | CA$15.0b | CA$13.1b | -CA$9,361,926,624.00 | 13.7x | -1.6x | 1.1x |
| Sun, 21 May 2023 | CA$15.1b | CA$13.3b | -CA$10,456,113,561.00 | 10.4x | -1.4x | 1.1x |
| Tue, 18 Apr 2023 | CA$15.4b | CA$13.3b | -CA$9,935,898,141.00 | 10.4x | -1.6x | 1.2x |
| Thu, 16 Mar 2023 | CA$18.3b | CA$13.9b | -CA$10,612,184,167.00 | 9.1x | -1.7x | 1.3x |
| Sat, 11 Feb 2023 | CA$19.4b | CA$13.5b | -CA$10,282,726,920.00 | 10x | -1.9x | 1.4x |
| Mon, 09 Jan 2023 | CA$20.4b | CA$13.5b | -CA$10,110,238,505.00 | 13.4x | -2x | 1.5x |
Price to Earnings Ratio
-2x
Current Industry PE
- Investors are relatively neutral on the Canadian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 1.4x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 6.1% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Trends
Which industries have driven the changes within the Canadian Healthcare industry?
| CA Market | -0.50% | |
| Healthcare | -1.00% | |
| Pharma | -2.26% | |
| Pharma | -2.26% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| TRUL Trulieve Cannabis | CA$11.91 | 9.3% +CA$171.0m | 45.4% | PS1.2x | |
| NGEN NervGen Pharma | CA$7.68 | 7.0% +CA$39.6m | 141.5% | PE-23.8x | |
| GRIN Grown Rogue International | CA$0.70 | 7.7% +CA$12.5m | -25.5% | PE19.9x | |
| VRNO Verano Holdings | CA$1.74 | 1.8% +CA$10.9m | -9.4% | PS0.6x | |
| CXXI C21 Investments | CA$0.53 | 17.8% +CA$9.4m | 107.8% | PS1.4x |
